drugset / Trial / NCT05378737
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Non-randomizedSequentialOpen-labelTreatment
Summary
Objectives: To evaluate the safety and tolerability of BAT8006 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
Timeline
- Start
- 2022-07-06
- Primary completion
- 2025-12-08
- Completion
- 2025-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT8006 | Monoclonal antibody | 1.2 mg/kg | Intravenous |
| Subject | BAT8006 | Monoclonal antibody | 2.4 mg/kg | Intravenous |
| Subject | BAT8006 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | BAT8006 | Monoclonal antibody | 3.6 mg/kg | Intravenous |
| Subject | BAT8006 | Monoclonal antibody | 84 mg/m2 | Intravenous |
| Subject | BAT8006 | Monoclonal antibody | 93 mg/m2 | Intravenous |